Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). Its late-stage investigational once-daily norepinephrine reuptake inhibitor, Ampreloxetine is in the development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California. Show more

Location: 901 Gateway Boulevard, South San Francisco, CA, 94080, United States | Website: https://www.theravance.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

759.4M

52 Wk Range

$7.90 - $15.34

Previous Close

$15.08

Open

$15.57

Volume

1,462,316

Day Range

$15.57 - $18.96

Enterprise Value

450.5M

Cash

338.8M

Avg Qtr Burn

N/A

Insider Ownership

4.37%

Institutional Own.

93.62%

Qtr Updated

06/30/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
TRELEGY ELLIPTA Details Chronic obstructive pulmonary disease (COPD)	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
YUPELRI® (revefenacin) Details Chronic obstructive pulmonary disease	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TRELEGY ELLIPTA Details Asthma	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ampreloxetine (TD-9855) Details Multiple System Atrophy, Neurogenic orthostatic hypotension	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Izencitinib (TD-1473) (GUT-SELECTIVE JAK INHIBITOR) Details Inflammatory bowel disease, Inflammatory disease, Ulcerative colitis, Crohns disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Nezulcitinib (TD-0903) (Janus kinase inhibitor (JAKi)) Details COVID-19, Skin disease/disorder	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Izencitinib (TD-1473) (GUT-SELECTIVE JAK INHIBITOR) Details Crohns disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.